Actualités Theratechnologies Inc - TH | Actions Toronto Stock Exchange

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Theratechnologies to Announce Third Quarter 2024 Financial Results and Provide Business Update

MONTREAL, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”...

Theratechnologies Announces a Risk of a Temporary Supply Disruption for EGRIFTA SV® in Early 2025

MONTREAL, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”...

Theratechnologies to Present at Upcoming Investor Conferences in September

MONTREAL, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”...

Theratechnologies Reports Financial Results and Announces Positive Net Income for Second Quarter 2024

Q2 revenue of $22 million represents +25% growth year-over-yearPositive net income of $1 million realized with...

Theratechnologies to Announce Second Quarter 2024 Financial Results and Provide Business Update

MONTREAL, June 26, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”...

Theratechnologies’ Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors

Poster highlights durable disease stabilization lasting beyond treatment completionResults suggest a unique...

Theratechnologies Reports on its Annual Meeting of Shareholders

MONTREAL, May 09, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”...

Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting

First long-term data presentation from Parts 1 and 2 of the Phase 1 clinical trial of sudocetaxel zendusortide...

Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders

MONTREAL, April 15, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”...

Theratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

MONTREAL, April 11, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”...

Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024

Q1 2024 consolidated revenue of $16.2 million Report marks third consecutive quarter of near-flat-to-positive...

Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platform

Novel camptothecin-peptide conjugates are well tolerated and associated with significant tumor regression in...

Theratechnologies Appoints Elina Tea to its Board of Directors

MONTREAL, April 05, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”...

Theratechnologies to Announce First Quarter 2024 Financial Results and Provide Business Update

MONTREAL, April 03, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”...

Theratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology™ Platform

Study to assess new camptothecin-peptide conjugates for the treatment of sortilin-positive colorectal cancers...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Theratechnologies Inc (TH)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

TH Actualités

Theratechnologies to Announce Third Quarter 2024 Financial Results and Provide Business Update

Theratechnologies Announces a Risk of a Temporary Supply Disruption for EGRIFTA SV® in Early 2025

Theratechnologies to Present at Upcoming Investor Conferences in September

Theratechnologies Reports Financial Results and Announces Positive Net Income for Second Quarter 2024

Theratechnologies to Announce Second Quarter 2024 Financial Results and Provide Business Update

Theratechnologies’ Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors

Theratechnologies Reports on its Annual Meeting of Shareholders

Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting

Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders

Theratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024

Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platform

Theratechnologies Appoints Elina Tea to its Board of Directors

Theratechnologies to Announce First Quarter 2024 Financial Results and Provide Business Update

Theratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology™ Platform

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Theratechnologies Inc (TH) Actualités

Theratechnologies Inc (TH)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

TH Actualités

Theratechnologies to Announce Third Quarter 2024 Financial Results and Provide Business Update

Theratechnologies Announces a Risk of a Temporary Supply Disruption for EGRIFTA SV® in Early 2025

Theratechnologies to Present at Upcoming Investor Conferences in September

Theratechnologies Reports Financial Results and Announces Positive Net Income for Second Quarter 2024

Theratechnologies to Announce Second Quarter 2024 Financial Results and Provide Business Update

Theratechnologies’ Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors

Theratechnologies Reports on its Annual Meeting of Shareholders

Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting

Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders

Theratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024

Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platform

Theratechnologies Appoints Elina Tea to its Board of Directors

Theratechnologies to Announce First Quarter 2024 Financial Results and Provide Business Update

Theratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology™ Platform

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités